Evaluation of molecular crystal structures using Full Interaction Maps

The specific crystalline form of a compound has a significant impact on its solid state properties. A key requirement for chemists developing crystalline materials is therefore to understand and evaluate the crystal form under investigation. We show here how the visualisation of molecular interaction maps within the context of a crystal structure can be used to evaluate the stability of polymorphic structures, assess multiple types of non-covalent interactions and provide a platform for crystal morphology analysis. Examples of three industrially-relevant compounds – sulfathiazole, anastrozole and cipamfylline – illustrate this well. A qualitative agreement with experimental stability data is observed for the five sulfathiazole crystal forms. The anastrozole crystal structure is demonstrated to optimise interactions to the strongest acceptor sites even though there are no conventional hydrogen-bond donors in the structure. Finally, the fastest growing plane of the needle-like morphology of cipamfylline is shown to have more H-bond donor and acceptor interactions per surface area than the slower growing planes.

[1]  K. Shankland,et al.  Rational modification of the hierarchy of intermolecular interactions in molecular crystal structures by using tunable halogen bonds. , 2009, Chemistry.

[2]  Frank H. Allen,et al.  Hydrogen-bond directionality at the donor H atom—analysis of interaction energies and database statistics , 2009 .

[3]  Afshan Mohajeri,et al.  Theoretical studies on the nature of bonding in σ-hole complexes , 2009 .

[4]  Michael B. Hursthouse,et al.  Packing similarity in polymorphs of sulfathiazole , 2008 .

[5]  Narayan Variankaval,et al.  From Form to Function: Crystallization of Active Pharmaceutical Ingredients , 2008 .

[6]  C. Macrae,et al.  Mercury CSD 2.0 – new features for the visualization and investigation of crystal structures , 2008 .

[7]  A. Gavezzotti,et al.  X-ray diffraction and theoretical studies for the quantitative assessment of intermolecular arene-perfluoroarene stacking interactions. , 2006, Chemistry.

[8]  G. Tang,et al.  2-[3-(2-Cyano-2-propyl)-5-(1,2,4-triazol-1-yl)phen­yl]-2-methyl­propiononitrile , 2005 .

[9]  Pierangelo Metrangolo,et al.  Halogen bonding based recognition processes: a world parallel to hydrogen bonding. , 2005, Accounts of chemical research.

[10]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[11]  W. L. Jorgensen.  The Many Roles of Computation in Drug Discovery , 2004, Science.

[12]  Changquan Calvin Sun,et al.  Influence of Crystal Structure on the Tableting Properties of Sulfamerazine Polymorphs , 2001, Pharmaceutical Research.

[13]  J. Bauer,et al.  Ritonavir: An Extraordinary Example of Conformational Polymorphism , 2001, Pharmaceutical Research.

[14]  Michael J. Cima,et al.  Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  K. Morris,et al.  Reactivity differences of indomethacin solid forms with ammonia gas. , 2002, Journal of the American Chemical Society.

[16]  C. Griffiths,et al.  Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17‐butyrate cream for the treatment of atopic dermatitis , 2002, The British journal of dermatology.

[17]  C Richard A Catlow,et al.  Theoretical and experimental investigations on the morphology of pharmaceutical crystals. , 2002, Journal of pharmaceutical sciences.

[18]  F. Allen.  The Cambridge Structural Database: a quarter of a million crystal structures and rising. , 2002, Acta crystallographica. Section B, Structural science.

[19]  P. Willett,et al.  SuperStar: improved knowledge-based interaction fields for protein binding sites. , 2001, Journal of molecular biology.

[20]  F. Sadeghi,et al.  Crystal Habit Modifications of Ibuprofen and Their Physicomechanical Characteristics , 2001, Drug development and industrial pharmacy.

[21]  C. A. Mitchell,et al.  Thermochemistry and Conformational Polymorphism of a Hexamorphic Crystal System , 2000 .

[22]  Michael B. Hursthouse,et al.  A new polymorph of sulfathiazole , 1999 .

[23]  Robin Taylor,et al.  SuperStar: a knowledge-based approach for identifying interaction sites in proteins. , 1999, Journal of molecular biology.

[24]  R. Davey,et al.  Disappearing polymorphs and the role of reaction by-products: the case of sulphathiazole , 1998 .

[25]  Robin Taylor,et al.  IsoStar: A library of information about nonbonded interactions , 1997, J. Comput. Aided Mol. Des..

[26]  T. Ishida,et al.  Structure of 5-methoxy-2-([4-methoxy-3,5-dimethyl-2-pyridinyl) methyl]sulfinyl)-1H-benzimidazole (omeprazole). , 1989, Acta crystallographica. Section C, Crystal structure communications.

[27]  G. Kruger,et al.  The crystal structure of sulphathiazole II , 1971 .

[28]  D. Harker,et al.  A new law of crystal morphology extending the law of Bravais , 1937 .